| Project/Area Number |
15590648
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
KAWAMOTO Hirofumi Okayama University, University Hospital, Research Associate, 医学部・歯学部附属病院, 助手 (60359883)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SHIRAHA Hidenori Okayama University, University Hospital, Research Associate, 医学部・歯学部附属病院, 助手 (40379748)
白鳥 康史 岡山大学, 大学院・医歯学総合研究科, 教授 (70196624)
|
|---|
| Project Period (FY) |
2003 – 2005
|
| Project Status |
Completed (Fiscal Year 2005)
|
| Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2005: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 2004: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 2003: ¥1,500,000 (Direct Cost: ¥1,500,000)
|
|---|
| Keywords | pancreatic cancer / genetic mutation / cell proliferation / metastasis |
|---|
| Research Abstract |
In the current study, we investigate the relationship between genetic mutation and sensitivity against anti-cancer drug in pancreatic cancer. We analyze the genetic mutation of RUNX3 as well as p53 and Rb. RUNX3 expression was analyzed by RT-PCR and Western blot analysis. Pancreatic cancer cell line QGP-1 express RUNX3, while KP-1 and KP-3 did not express RUNX3. We introduce RUNX3 cDNA into KP-1 and KP-3. RUNX3 introduction resulted in reduction of cell number by 〜20%. Apoptosis was evaluated by FACS using anti-Annexin V antibody. RUNX3 introduced cells showed 〜30% increase of apoptosis. On the other hand RUNX3 knockdown using RNAi resulted in increment of cell proliferative activity. As for k-ras mutation, k-ras mutation also increased cell proliferative activity in pancreatic cancer. We also analyzed the relationship between k-ras mutation and effectiveness of anti-cancer drugs (gemcitabine, gemcitabine-cisplatin). K-ras mutation did not have significant effect on patient survival treated with gemcitabine or gemcitabine-cisplatin.
In conclusion, #1 genetic mutation in k-ras and/or RUNX3 increased malignantpotential of pancreatic cancer. #2 k-ras mutation did not affect the sensitivity against anti-cancer drug in pancreatic cancer.
|
